Israeli Startup Undecimal Bio Develops AI Platform for Targeted Drug Delivery
Translated & summarized from NEWSru Israel by baba
Israeli startup Undecimal Bio has created the DELiveri platform, using AI and combinatorial chemistry to deliver genetic drugs to specific diseased cells. Current methods struggle to reach organs beyond the liver, but DELiveri screens large compound libraries and uses cells as detectors to find effective carriers. The company raised $18 million in seed funding for further development and initial treatment programs.
The story in 5 lines · by baba
- Undecimal Bio's DELiveri platform uses AI and chemistry to target drug delivery to specific cells.
- The platform screens vast libraries of chemical compounds, overcoming limitations of current delivery methods.
- Cells act as detectors, registering drug entry at a molecular level for AI analysis.
- Co-founder Yaniv Erlich highlighted delivery as the key challenge for RNA interference therapies.
- The startup secured $18 million in seed funding for technology development and treatment programs.
Israeli startup Undecimal Bio has developed a platform called DELiveri, designed to deliver genetic medicines to specific diseased cells within the body. RNA interference-based drugs can silence faulty genes to treat serious illnesses, but precisely targeting affected tissues has been a significant challenge. Current delivery methods are often limited to liver cells, leaving other organs difficult to reach.
DELiveri utilizes a combination of combinatorial chemistry and artificial intelligence to overcome this hurdle. Instead of testing individual carrier molecules, the platform screens vast libraries of chemical compounds simultaneously. Cells themselves act as detectors, registering drug entry at a molecular level. This data is then analyzed by autonomous AI agents to identify correlations between compound structures and their ability to penetrate specific cell types, enabling a rapid and systematic search for new delivery systems.
The company's creators emphasize that drug delivery is crucial for the future of genetic medicine. "The main problem with RNA interference has never been the gene silencing itself, the problem is getting the molecule to the right cell," stated Undecimal Bio co-founder and CEO Yaniv Erlich.
Undecimal Bio has successfully raised $18 million in seed funding to advance its technology and develop initial treatment programs for cardiovascular and kidney diseases.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
